Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis.

Primary tabs

Average: 5 (1 vote)
Therapeutic intervention: 
Therapeutic Substance(s): 
Publication type: 

Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis.
Mehta S, Boddy A, Johnson IT, Rhodes M.
Department of Upper Gastrointestinal Surgery, Norfolk and Norwich University Hospital, Colney Lane, Norwich, UK.
Published in vitro and animal in vivo studies have demonstrated that
cyclo-oxygenase-2 plays an important role during oesophageal
adenocarcinogenesis. However, the extent to which these studies are
directly relevant to events in the human lower oesophagus is
questionable. AIM: To perform a systematic review of all available
human studies that have evaluated levels of cyclo-oxygenase-2
expression during the progression from Barrett's metaplasia to
oesophageal adenocarcinoma.
METHODS: A literature search was performed
to identify all studies which qualitatively or quantitatively assessed
cyclo-oxygenase-2 protein or gene expression in either Barrett's,
dysplastic or adenocarcinoma tissue in humans. RESULTS: A total of 27
studies met the inclusion criteria. There was general agreement that
cyclo-oxygenase-2 was either absent or very weakly expressed in normal
oesophageal squamous mucosa, but considerable disagreement regarding
the presence of cyclo-oxygenase-2 in Barrett's and low-grade dysplasia.
All studies agreed that high-grade dysplasia and adenocarcinoma
expressed cyclo-oxygenase-2 to some extent although levels varied
considerably between tissue samples.
CONCLUSIONS: There is conflicting
evidence in the literature for cyclo-oxygenase-2 playing an important
role in early oesophageal adenocarcinogenesis. Other
non-cyclo-oxygenase-2 targets may account for the epidemiological data
supporting the use of non-steroidal anti-inflammatory drugs in the
chemoprevention of oesophageal adenocarcinoma.